Sweet-liking and sugar supplementation as innovative components in substance use disorder treatment: A systematic review.

IF 4.5 3区 医学 Q1 CLINICAL NEUROLOGY
Jan van Amsterdam, Wim van den Brink
{"title":"Sweet-liking and sugar supplementation as innovative components in substance use disorder treatment: A systematic review.","authors":"Jan van Amsterdam, Wim van den Brink","doi":"10.1177/02698811251319454","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Substance use disorders are a major global public health concern. While a wide range of psychotherapies and pharmacotherapies are available for their treatment, efficacy is limited and many patients fail to benefit from these treatments. Like addictive substances, sugar seems to trigger the dopaminergic reward centre, and sweet-liking might be a modifier of substance use disorder treatment.</p><p><strong>Method: </strong>Systematic review to summarize the role of sugar and sugar-liking in addiction and addiction treatment.</p><p><strong>Results: </strong>Evidence from both preclinical and clinical studies suggests that a certain portion of the population has a genetic predisposition for sweet-liking, which might be related to a higher risk for substance use and dependence. Regarding nicotine dependence, glucose supplementation prior to or during smoking cessation rapidly mitigates withdrawal symptoms and increases smoking abstinence rates during nicotine replacement therapy. In alcohol dependence, sweet-liking patients encounter more challenges in achieving abstinence than sweet-disliking patients. In addition, sweet-liking patients with high cravings demonstrate higher abstinence rates than sweet-disliking patients. Finally, sweet-liking is associated with successful outcomes of naltrexone treatment in patients with an alcohol use disorder.</p><p><strong>Conclusion: </strong>These findings present promising new challenges and opportunities to fine-tune and optimize treatment protocols in addiction care.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251319454"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811251319454","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Substance use disorders are a major global public health concern. While a wide range of psychotherapies and pharmacotherapies are available for their treatment, efficacy is limited and many patients fail to benefit from these treatments. Like addictive substances, sugar seems to trigger the dopaminergic reward centre, and sweet-liking might be a modifier of substance use disorder treatment.

Method: Systematic review to summarize the role of sugar and sugar-liking in addiction and addiction treatment.

Results: Evidence from both preclinical and clinical studies suggests that a certain portion of the population has a genetic predisposition for sweet-liking, which might be related to a higher risk for substance use and dependence. Regarding nicotine dependence, glucose supplementation prior to or during smoking cessation rapidly mitigates withdrawal symptoms and increases smoking abstinence rates during nicotine replacement therapy. In alcohol dependence, sweet-liking patients encounter more challenges in achieving abstinence than sweet-disliking patients. In addition, sweet-liking patients with high cravings demonstrate higher abstinence rates than sweet-disliking patients. Finally, sweet-liking is associated with successful outcomes of naltrexone treatment in patients with an alcohol use disorder.

Conclusion: These findings present promising new challenges and opportunities to fine-tune and optimize treatment protocols in addiction care.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Psychopharmacology
Journal of Psychopharmacology 医学-精神病学
CiteScore
8.60
自引率
4.90%
发文量
126
审稿时长
3-8 weeks
期刊介绍: The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信